ArticleInternational journal of oncology2018

FSCN‑1 increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transition.

Yuanbiao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.